Responses
Regular and young investigator award abstracts
Clinical trials in progress
353 Safety and efficacy of tumor infiltrating lymphocytes (TIL, LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC
Compose a Response to This Article
Other responses
No responses have been published for this article.
